1566TiP PRODIGE 65 - UCGI 36 - GEMPAX : A unicancer phase III randomized study evaluating gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in metastatic pancreatic ductal adenocarcinoma

Autor:	Marine Jary, Pierre Michel, Damien Botsen, F. Hociné, Pascal Hammel, Thomas Aparicio, Sylvie Chabaud, Nicolas Lachaux, Cindy Neuzillet, François Ghiringhelli, A. Peytier, S. Launay, Claire Cropet, Ludovic Evesque, Angélique Vienot, J. Raimbourg, Laetitia Dahan, J.M. Phelip, C. de la Fouchardiere, Hervé Perrier
Rok vydání:	2020
Předmět:	Oncology medicine.medical_specialty Pancreatic ductal adenocarcinoma business.industry FOLFIRINOX Hematology Gemcitabine law.invention chemistry.chemical_compound Paclitaxel chemistry Randomized controlled trial law Internal medicine Medicine business medicine.drug
Zdroj:	Annals of Oncology. 31:S954-S955
ISSN:	0923-7534
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::f41e1091e57119a10b952662cc764313 https://doi.org/10.1016/j.annonc.2020.08.2049 Zobrazit plný text záznamu